The Leckie Protocol: A Dual-Route Administration Method for 5-MeO-DMT
The world's most powerful psychedelic just went mainstream. We've been preparing for this conversation for a long time.
Enfold Institute | Canada | V1.0 | March 25, 2026 | Enfold.org
Abstract
The Leckie Protocol describes a novel dual-route administration method for 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), combining a consecutive intramuscular (IM) injection and vaporized inhalation to produce a compound pharmacological effect that draws on the distinct properties of each route. Developed and refined by Enfold Institute over multiple years of clinical observation across 650+ facilitated guest sessions, this protocol is administered within a structured 5-day therapeutic process incorporating pre-session preparation, supervised ceremonies, and post-session integration support. This document describes the rationale, methodology, dose parameters, and contextual framework of the protocol.
1. Background and Institutional Context
Enfold Institute has been delivering 5-MeO-DMT therapeutic experiences since 2019, accumulating a dataset of 650+ guest sessions with detailed session notes and tracked outcomes, alongside hundreds of additional internal research sessions. The institute has contributed to FDA Clinical Protocol Design consultation and has recently completed data collection for a formal observational study conducted in partnership with the University Health Network and the University of Toronto. The observational study includes approximately 45 participants that have received the Leckie Protocol and will likely be published late 2026 or early 2027.
Enfold’s facilitation peri-session model is grounded in a psycho-spiritual framework addressing the whole person across three interconnected systems: the nervous system, the personality system, and the spiritual system. Rather than treating the 5-MeO-DMT experience as purely psychological or pharmacological, Enfold understands the medicine as fundamentally energetic and somatic — creating conditions for deep recalibration across all dimensions of the self. Preparation spans three weeks of daily structured material introducing embodiment practices, interoceptive awareness, and nervous system regulation prior to arrival. Post-session support encompasses a dedicated recalibration phase followed by formal integration, delivered through individual coaching, group integration calls, and ongoing community engagement. Drawing on modalities including Internal Family Systems (IFS), somatic therapy, and trauma-informed practices alongside wisdom traditions including Buddhist philosophy, Enfold’s approach is deliberately non-dogmatic, designed to meet participants across the full spectrum of spiritual and psychological worldviews.
2. Pharmacological Rationale for Dual-Route Administration
2.1 Properties of Vaporized 5-MeO-DMT
Vaporized administration of 5-MeO-DMT produces rapid onset (seconds) and a comparatively brief duration of peak effect. At high doses, the vaporized route reliably produces the full non-dual, ego-dissolving state characteristic of the compound — driven by an acute, high-velocity saturation of relevant receptor sites. A defining feature of this route is the powerful somatic and energetic discharge it elicits in the nervous system: participants commonly experience an intense, full-body release that is unparalleled among known psychedelic compounds. This response appears to operate below the level of cognitive processing — less a psychological experience than a direct physiological event, in which the nervous system rapidly discharges accumulated tension, trauma, and dysregulation. It is this quality that gives vaporized 5-MeO-DMT its distinctive therapeutic potential, independent of narrative or insight. Because the saturation is fast-metabolizing, however, the peak is brief, and participants frequently report limited episodic memory of the experience — underscoring the somatic, rather than cognitive, nature of its primary mechanism of action.
2.2 Properties of Intramuscular 5-MeO-DMT
Intramuscular administration presents a markedly different pharmacodynamic profile. Onset is substantially slower — typically 3–5 minutes — and the plateau extends to approximately 30–45 minutes, in contrast to the acute, high-velocity peak of vaporized delivery. Where vaporized administration overwhelms ego resistance through sheer onset velocity, the slower saturation rate of the IM route gives the ego adequate time to respond and reassert itself, making the full non-dual state — and the pronounced somatic nervous system release that accompanies it — considerably more difficult to achieve. What IM administration offers instead is duration: a sustained, gentler engagement with the medicine that allows participants greater opportunity for conscious participation in the therapeutic process. The IM experience tends toward a prolonged, navigable altered state — therapeutically valuable, but distinct in mechanism from the acute somatic release of the vaporized route.
2.3 Rationale for Combination
Administered simultaneously, the two routes produce a synergistic pharmacological profile. The vaporized dose achieves rapid, full-saturation onset and the characteristic full ego dissolution and the profound somatic nervous system release. As the vaporized component begins to metabolize — typically within a few minutes — the intramuscular dose reaches onset and extends the experience into a sustained therapeutic plateau. The result is a session architecture that combines the depth of the vaporized peak with the duration and working time of the intramuscular route. Importantly, vaporized administration alone does not offer this extended window, and intramuscular administration alone does not reliably achieve the full non-dual state. The Leckie Protocol resolves this tradeoff by leveraging both simultaneously.
3. Therapeutic Container and Clinical Context
3.1 Therapeutic Container
The Leckie Protocol is administered exclusively within Enfold’s 5-day Awakening to Life intensive. Sessions are conducted in small groups with a 2:1 guest-to-facilitator ratio. The protocol is not administered in isolation; it is embedded within a comprehensive psycho-spiritual therapeutic process that addresses three interconnected systems: the nervous system, the personality system, and the spiritual system.
Prior to arrival, each participant completes a holistic intake assessment, a 3-week preparation program including a structured video education series, and two preparation calls with facilitators.
On day one, guests participate in a low-dose ceremony involving multiple vaporized administrations of 5-MeO-DMT in the 1–1.5mg range. This serves three purposes: introducing guests to the felt qualities of the compound, priming the nervous system for deeper work, and giving facilitators direct observational data on each individual’s sensitivity and response. We consider this low-dose session a prerequisite before any high-dose administration.
Day two includes a workshop exploring themes, story, and underlying psychological and somatic patterning, helping guests develop a clear contextual framework for the work ahead.
The high-dose Leckie Protocol ceremony is conducted on day three, in a private setting with the guest and two dedicated facilitators.
Days four and five include multiple integration practices, sessions, and workshops oriented around recalibration across all three systems. Guests remain under supervision for two additional nights following the high-dose ceremony. Post-intensive, all guests receive four weeks of on-call support, two integration calls with facilitators, extensive integration resources, lifetime invitations to community calls, and access to a network of psychedelic-informed therapists and coaches.
3.2 Client Population
The typical Enfold client is between 35 and 75 years of age (modal range: 40s–60s), is psychologically stable and generally well-functioning at time of intervention. Many clients present with a history of trauma spanning a spectrum from serious traumatic experiences to common patterns of childhood adversity.
The Leckie Protocol is not appropriate for individuals experiencing acute dysregulation in their lives. Any administration of 5-MeO-DMT requires expert clinical oversight and facilitation. Contraindications and screening criteria should always be thoroughly assessed during the intake process.
4. Dosing Parameters
4.1 Individualized Dosing Philosophy
Body mass has not been found to be a reliable predictor of individual response to 5-MeO-DMT. Dose selection is determined by the following factors: baseline sensitivity to 5-MeO-DMT, prior experience with the compound or other psychedelics, ego structure and psychological flexibility, current mental state and stability, and the therapeutic goals of the session. The low-dose ceremony on day one of our process provides direct physiological and psychological data to inform dose calibration for the high-dose ceremony.
4.2 Administration Sequence
The IM dose is administered first. The vaporized dose follows immediately afterwards. Given the 3–5 minute IM onset, the participant will experience the vaporized dose first within 5-10 seconds, with the IM component becoming perceptible as the vaporized dose begins to metabolize at the 4-5 minute range.
4.3 Dose Ranges
Intramuscular: Typical range: 6mg–9mg freebase equivalent (minimum reported: 4.5mg). When using Succinate salt (approximately 65% 5-MeO-DMT by weight), a dose of 9mg Succinate equates to approximately 6mg freebase. HCL salt form (approximately 85% by weight) should be adjusted accordingly.
Vaporized (freebase): Typical range: 10mg–18mg.
4.4 Notes on Vaporized Dose Accuracy
Accurate dose measurement requires a calibrated 4-point scientific scale; standard gemological scales are insufficient for reliable dosing at this precision. Freebase purity is a critical variable in dose measurement —we always recommend working directly with manufactures and completing your own independent batch-based 3rd party testing to understand potency. Vaporization devices with larger chamber volumes or those that pre-vaporize material into a chamber prior to inhalation may require higher doses to achieve equivalent saturation due to loss inside the device.
4.5 Notes on IM Preparation and Safety
Intramuscular administration of 5-MeO-DMT requires verified 99%+ purity. Third-party laboratory testing is required prior to use. Material must be prepared as a liquid solution in bacteriostatic water using sterile equipment, micron filtration, a lab-grade 4-point scale, and established best practices for injectable preparation. The use of toad-derived 5-MeO-DMT (Bufo alvarius secretion) for injection is categorically contraindicated and presents serious physiological risk.
5. Saturation Curve Analysis
The pharmacodynamic interaction between routes can be modeled as a saturation curve. Note: this is based on 200+ sessions delivered and documented under the Leckie Protocol — no published clinical research on blood plasma saturation (Cmax) currently exists.
In the representative session above — IM: 9mg Succinate (~6mg freebase); Vaporized: 18mg freebase — peak activation approximates the total vaporized dose. The IM component does not meaningfully raise the peak; instead, it sustains saturation as the vaporized component clears.
6. Disclaimer
This document is intended for informational and educational purposes only. It does not constitute medical advice and should not be interpreted as a clinical recommendation. The administration of 5-MeO-DMT carries significant physiological and psychological risks and should only be undertaken under expert supervision. Practitioners are advised to conduct independent research and consult applicable legal and medical frameworks in their jurisdiction.